SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of PTC Therapeutics, Inc. - PTCT

Group 1 - Pomerantz LLP is investigating claims on behalf of investors of PTC Therapeutics, Inc. regarding potential securities fraud or unlawful business practices by the company and its officers [3][5]. - On June 28, 2024, PTC's stock price dropped by $4.08 per share, representing an 11.77% decline, closing at $30.58 per share [4]. - The decline in stock price followed PTC's announcement that the European Medicines Agency's Committee for Medicinal Products for Human Use issued a negative opinion on the renewal of the conditional marketing authorization of Translarna™ (ataluren) for treating nmDMD [6]. Group 2 - Pomerantz LLP has a long history of fighting for the rights of victims of securities fraud and has recovered billions of dollars in damages on behalf of class members [2].